Publication:
Effect of comorbidities on long-term outcomes of colorectal cancer patients.

dc.contributor.authorQuintana, José M
dc.contributor.authorAnton-Ladislao, Ane
dc.contributor.authorLázaro, Santiago
dc.contributor.authorGonzalez, Nerea
dc.contributor.authorBare, Marisa
dc.contributor.authorFernandez-de-Larrea, Nerea
dc.contributor.authorRedondo, Maximino
dc.contributor.authorEscobar, Antonio
dc.contributor.authorSarasqueta, Cristina
dc.contributor.authorGarcia-Gutierrez, Susana
dc.contributor.authorAguirre, Urko
dc.contributor.authorREDISSEC-CARESS/CCR group
dc.date.accessioned2023-05-03T13:28:48Z
dc.date.available2023-05-03T13:28:48Z
dc.date.issued2022-02-16
dc.description.abstractThe objective of this work is to evaluate the association of comorbidities with various outcomes in patients diagnosed with colon or rectal cancer. We conducted a prospective cohort study of patients diagnosed with colon or rectal cancer who underwent surgery. Data were gathered on sociodemographic, clinical characteristics, disease course, and the EuroQol EQ-5D and EORTC QLQ-C30 scores, up to 5 years after surgery. The main outcomes of the study were mortality, complications, readmissions, reoperations, and changes in PROMs up to 5 years. Multivariable multilevel logistic regression models were used in the analyses. Mortality at some point during the 5-year follow-up was related to cardiocerebrovascular, hemiplegia and/or stroke, chronic obstructive pulmonary disease (COPD), diabetes, cancer, and dementia. Similarly, complications were related to cardiovascular disease, COPD, diabetes, hepatitis, hepatic or renal pathologies, and dementia; readmissions to cardiovascular disease, COPD, and hepatic pathologies; and reoperations to cerebrovascular and diabetes. Finally, changes in EQ-5D scores at some point during follow-up were related to cardiocerebrovascular disease, COPD, diabetes, pre-existing cancer, hepatic and gastrointestinal pathologies, and changes in EORTC QLQ-C30 scores to cardiovascular disease, COPD, diabetes, and hepatic and gastrointestinal pathologies. Optimising the management of the comorbidities most strongly related to adverse outcomes may help to reduce those events in these patients.
dc.identifier.doi10.1111/ecc.13561
dc.identifier.essn1365-2354
dc.identifier.pmid35174571
dc.identifier.unpaywallURLhttps://doi.org/10.1111/ecc.13561
dc.identifier.urihttp://hdl.handle.net/10668/19943
dc.issue.number2
dc.journal.titleEuropean journal of cancer care
dc.journal.titleabbreviationEur J Cancer Care (Engl)
dc.language.isoen
dc.organizationHospital Costa del Sol
dc.page.numbere13561
dc.pubmedtypeJournal Article
dc.rights.accessRightsopen access
dc.subjectcolorectal cancer
dc.subjectcomorbidity
dc.subjectoutcomes
dc.subjectprospective cohort
dc.subject.meshComorbidity
dc.subject.meshHumans
dc.subject.meshLogistic Models
dc.subject.meshProspective Studies
dc.subject.meshQuality of Life
dc.subject.meshRectal Neoplasms
dc.titleEffect of comorbidities on long-term outcomes of colorectal cancer patients.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number31
dspace.entity.typePublication

Files